person · Reporting owner
Woodman Richard Charles
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Traws Pharma, Inc.ONTX · Entity 8032 | Chief Medical Officer | July 09, 2020 | July 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Traws Pharma, Inc.
Report date July 09, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2030-07-09 | Direct | 396,000 |
Reported balance
After 2020-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 396,000 · Balance 396,000 F1: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2020 Filed Jul 10, 2020 21:46 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 396,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008211 · edgar.xml · derivative · entry 1 Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:11 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 80,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013141 · edgar.xml · derivative · entry 1 Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 22:10 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0001179110-18-012642 · edgar.xml · derivative · entry 1 Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: These options vest over 4 years. 25% on the first anniversary of the grant date and the remainder in 36 equal monthly installments over the last 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.